India’s pharmaceutical retail market rebounded in November with double-digit growth, driven by increased demand for dermatological and cardiac medications. Respiratory issues, exacerbated by pollution, boosted Foracort sales to Rs 82 crore. Both acute and chronic medications saw 11% growth, and industry volumes rose by 3.5%. Analysts predict continued growth in 2025, fueled by price increases and new drug launches.
Related Posts
Stocks on brokerages’ radar for December 19
Citi maintained a ‘buy’ rating for LIC Housing Finance with a target of Rs 851. Nuvama upgraded Coromandel International to ‘buy’ with a target of […]
Sebi imposes Rs 9 lakh penalty on BGR Energy Systems for disclosure lapses
The Securities and Exchange Board of India (Sebi) has levied a Rs 9 lakh fine on BGR Energy Systems for non-compliance with disclosure norms and […]
Maruti Suzuki India total sales decline 4% in August
Maruti Suzuki India experienced a 4% drop in total sales compared to the same month last year, with 1,81,782 units sold. Domestic passenger vehicle sales […]